Login / Signup

Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.

Josephine D HendriksenAlessio LocalloSimone MaarupOlivia DebnathNaveed IshaqueBenedikte HasselbachJane Skjøth-RasmussenChristina Westmose YdeHans S PoulsenUlrik LassenJoachim Weischenfeldt
Published in: Neuro-oncology (2024)
We find a resistance mechanism signature in a quarter of glioblastoma patients associated with a tumour-cell transition to a more aggressive mesenchymal-like state, increase in TAMs and proliferative and exhausted T cells in response to immunotherapy. These patients may instead benefit from neuro-oncology therapies targeting mesenchymal tumour cells.
Keyphrases